Medtech companies are preparing for a day when telesurgery, performed by a surgeon often hundreds of miles from the patient, could become a viable option for more people.
Telerobotic surgery is advancing around the world. Will the US embrace it? Read More »
Novartis is the current radiopharma leader with two FDA-approved therapies in Pluvicto and Lutathera.
Novartis bets up to $900M for radioligand therapy from China’s BoomRay Read More »
A late-stage test of Roche and Ionis Pharmaceuticals’ sefaxersen showed that the drug reduced protein in the urine, which suggests the RNA-targeting therapy could improve kidney function and delay transplant.
Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod Read More »
Amgen is awaiting another Phase 3 readout for the investigational Sjögren’s disease therapy, set for later this year. William Blair anticipates that at least two trials will be needed to support an FDA application.
Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren’s study Read More »
Ulefnersen, an RNA-targeted therapy being developed by Ionis Pharmaceuticals and Otsuka Pharmaceutical, improved measurements of functional impairment and survival in patients with a rare, genetic ALS subtype in a Phase 3 trial. The partners plan to approach the FDA with the results to determine potential pathways for approval.
Novo plans to hit $23B in revenue by 2035, has further reduced its workforce by 4,000 and is boosting manufacturing capacity for its Wegovy pill, but investors are unconvinced it will be enough to turn things around; Viking Therapeutics and Roche report positive results for their weight loss assets; Ultragenyx snags FDA approval for its
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz Read More »
La historia de la ciencia está llena de giros inesperados, pero pocos tan paradigmáticos como el de John Bennett Fenn. Este químico estadounidense no solo revolucionó la bioquímica moderna al enseñar a «volar» a las moléculas de la vida, s …
De la jubilación forzosa al Premio Nobel: La vida de John B. Fenn Read More »
Comprender el universo es una de las grandes aspiraciones de la ciencia. Desde las primeras civilizaciones que observaron el movimiento de los astros hasta los modernos telescopios espaciales y los grandes aceleradores de partículas, nuestra especie ha dedicado miles de años a intentar …
Una breve historia del universo (Sarah Alam Malik) Read More »
En un entorno de supervivencia extremo, la oscuridad deja de ser una mera ausencia de luz para convertirse en una amenaza biológica activa. Cuando el aislamiento se suma a la penumbra, el cerebro humano activa mecanismos de defensa primarios que alteran la percepción, modifican la qu&i …
Cómo el cerebro procesa la oscuridad y el aislamiento Read More »
Looking for a biopharma job in Pennsylvania? Job postings in the state tripled year over year on BioSpace. These nine companies are hiring now.
